In patients with TP53-mutated MDS and acute myeloid leukemia, the burden of TP53 aberrations (high-risk vs. low-risk conditions based on the allelic state) significantly affects outcomes, with biallelic TP53 alterations associated with a poor prognosis [25]. The gene discussed is TP53; the disease is acute myeloid leukemia.